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Abstract
Melatonin is a powerful antioxidant and a synchronizer of many physiological processes. Alteration of the melatonin pathway
has been reported in circadian disorders, diabetes and autism spectrum disorders (ASD). However, very little is known about
the genetic variability of melatonin receptors in humans. Here, we sequenced the melatonin receptor MTNR1A and MTNR1B,
genes coding for MT1 and MT2 receptors, respectively, in a large panel of 941 individuals including 295 patients with ASD, 362
controls and 284 individuals from different ethnic backgrounds. We also sequenced GPR50, coding for the orphan melatonin-
related receptor GPR50 in patients and controls. We identified six non-synonymous mutations for MTNR1A and ten for
MTNR1B. The majority of these variations altered receptor function. Particularly interesting mutants are MT1-I49N, which is
devoid of any melatonin binding and cell surface expression, and MT1-G166E and MT1-I212T, which showed severely impaired
cell surface expression. Of note, several mutants possessed pathway-selective signaling properties, some preferentially
inhibiting the adenylyl cyclase pathway, others preferentially activating the MAPK pathway. The prevalence of these
deleterious mutations in cases and controls indicates that they do not represent major risk factor for ASD (MTNR1A case 3.6%
vs controls 4.4%; MTNR1B case 4.7% vs 3% controls). Concerning GPR50, we detected a significant association between ASD
and two variations, D502–505 and T532A, in affected males, but it did not hold up after Bonferonni correction for multiple
testing. Our results represent the first functional ascertainment of melatonin receptors in humans and constitute a basis for
future structure-function studies and for interpreting genetic data on the melatonin pathway in patients.
Citation: Chaste P, Clement N, Mercati O, Guillaume J-L, Delorme R, et al. (2010) Identification of Pathway-Biased and Deleterious Melatonin Receptor Mutants in
Autism Spectrum Disorders and in the General Population. PLoS ONE 5(7): e11495. doi:10.1371/journal.pone.0011495
Editor: Rafael Linden, Universidade Federal do Rio de Janeiro (UFRJ), Brazil
Received April 9, 2010; Accepted June 9, 2010; Published July 15, 2010
Copyright:  2010 Chaste et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Institut Pasteur, University Denis Diderot Paris 7, University Paris Descartes, INSERM, CNRS, Fondation pour la
Recherche Medicale (‘‘Equipe FRM’’, RJ), Foundation Orange, Fondation de France, Foundation FondaMentale, and by the Swedish Science Council. The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: ralf.jockers@inserm.fr
. These authors contributed equally to this work.
Introduction
Melatonin is synthesized in the pineal gland during the night
and is involved in various physiologic functions, including
sleep induction, circadian rhythm regulation, and immune
response [1]. Melatonin synthesis requires serotonin, which is
first acetylated by aryl alkylamine N-acetyltransferase (AA-NAT)
and then converted to melatonin by acetyl serotonin methyl
transferase (ASMT also known as hydroxyindole O-methyltrans-
ferase or HIOMT) [1]. Melatonin signaling is mainly mediated
by the guanine nucleotide binding (G) protein-coupled receptors
(GPCRs) MTNR1A (MT1)a n dMTNR1B (MT2)t h a ta r e
expressed in the suprachiasmatic nuclei (SCN) but are also
present in other hypothalamic nuclei, retina, immune cells, and
other peripheral organs. Established downstream cellular effects
of melatonin receptor activation are inhibition of the adenylyl
cyclase pathway and activation of the MAPK pathway [2]. The
melatonin related receptor GPR50 is an orphan GPCR with no
affinity for melatonin, but as a dimer with MT1, it inhibits
melatonin signaling [3].
Abnormal melatonin signaling has been reported as a risk
factor for medical conditions as diverse as diabetes mellitus,
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11495circadian rhythm and psychiatric disorders [4,5,6,7,8,9]. The
role of melatonin in the susceptibility to these disorders remains
unclear, but an alteration of melatonin as a powerful antioxidant
molecule and/or as a ‘‘Zeitgeber’’ (time giver) could alter and/or
desynchronize many physiological processes related to a broad
range of disorders. Sleep disorders are common in the general
population, and their incidence is higher in many psychiatric
disorders [9]. Abnormal sleep patterns have often been reported in
patients with autism [10,11,12] or Asperger syndrome [13,14,15],
a condition characterized by the presence of markedly autistic
behavior in people of normal general intelligence. Several studies
have indicated that melatonin treatment improves sleep in
autism [16,17,18,19], and in patients with Asperger syndrome
[20]. The main effect on sleep seems to be a reduction of sleep
onset latency.
We therefore decided to study the genetic variability of the
melatonin receptor MTNR1A and MTNR1B genes and the
GPR50 gene in autism spectrum disorder (ASD) patients, in
parallel to a normal European control population as well as in
individuals of the human genome pluriethnic diversity panel
(HGDP), by direct sequencing of the coding regions. Several
non-synonymous mutants were identified for MT1 and MT2
and their functional properties determined in different in vitro
assays.
Results
Identification of MTNR1A non-synonymous variants
Six non-synonymous mutations were identified for MTNR1A.
The MT1-I49N variant was detected in a patient with ASD, but
not in our control sample (Table 1). The patient carrying the
mutation has high functioning autism and clinical delayed sleep
phase syndrome (Table S1). Actimetry during three weeks showed
a delayed sleep onset. Mean time of sleep onset was shifted with
melatonin treatment from 0:52 AM to 11:36 PM. The mutation is
inherited from the unaffected father.
The MT1-I212T variant was identified in two affected twins
and another independent proband and not in controls. However
these patients were all from African descent and this mutation was
found in six individuals from African descent in the HGDP
(Yoruba and Mandenka). In both families the probands received
the mutation from their mother. The mother of the second family
who carries the mutation has epilepsy. The three boys show severe
mental retardation and severe autism without language. Sleep was
not recorded as a major problem.
The MT1-K334N variant was found in one proband, in two
controls, and in one individual from the HDGP Caucasian sample
(Basque). The proband carries also the relatively frequent MT1-
A266V mutation (allelic frequency of 1–4% in the general
Table 1. MTNR1A and MTNR1B variants identified in 295 patients with autism spectrum disorder, 362 controls, and 284 individuals
from the human genome diversity panel.
Variation
Genomic
position
a Allele Maj/Min Number of individuals carrying the variation (Allelic frequency%)
Receptor
function
ASD Controls HDGP Panel
Caucasians Asians Africans
(n=295) (n=362) (n=89) (n=107) (n=88)
MTNR1A (Chr4)
I49N 187476374 T/A 1 (0.17%) 0 0 0 0 Altered
A157V 187455426 C/T 0 0 0 1 (0.47%) 0 ND
G166E 187455399 G/A 6 (1%) 15 (2%) 2 (1.1%) 0 1 (0.57%) Altered
I212T 187455261 T/C 2 (0.33%) 0 0 0 6 (3.4%) Altered
A266V 187455099 C/T 11 (1.9%) 15 (2%) 4 (2.2%) 2 (0.93%) 5 (2.8%) Altered
K334N 187454894 A/T 1 (0.17%) 2 (0.28%) 1 (0.56%) 0 0 Altered
ALL
b 20 (3.6%) 30 (4.4%) 7 (3.9%) 3 (1.4%) 12 (6.8%)
MTNR1B (chr11)
A13V 92342577 C/T 0 0 0 1 (0.47%) 0 ND
G24E 92342610 G/A 4 AA 46 AG 245
GG f(A) 9.15%
1A A4 8A G3 1 3
GG f(A) 6.9%
3 AA 6 AG 80 GG
f(A) 6.7%
0 AA 8 AG 99 GG
f(A) 3.7%
0 AA 2 AG 86 GG
f(A) 1.1%
As control
A25T 92342612 G/A 0 0 0 0 1 (0.57%) ND
M120V 92354397 A/G 0 1 (0.14%) 0 0 0 As control
V124I 92354409 G/A 1 (0.17%) 0 0 0 0 Altered
R138C 92354449 C/T 1 (0.17%) 2 (0.28%) 0 0 0 Altered
R231H 92354729 G/A 3 (0.5%) 5 (0.69%) 1 (0.56%) 0 0 Altered
K243R 92354765 A/G 0 GG 22 AG 273
AA f(G) 3.7%
0 GG 15 AG 347
AA f(G) 2%
0 GG 3 AG 86 AA
f(G) 1.7%
0 GG 1 AG 106 AA
f(G)0.47%
3G G2 8A G5 1A A
f(G)19.3%
Altered
A325V 92355011 C/T 0 0 0 1 (0.47%) 0 ND
R330Q 92355026 G/A 1 (0.17%) 0 0 0 0 As control
ALL
b 74(13.9%) 67(10.1%) 13 (8.9%) 11 (5.1%) 33 (21%)
aHuman genome build NCBI36/hg18;
btotal of individuals carrying MTNR1A/B variations. This number can be lower than the number of variants since some individuals are carrying two variations.
doi:10.1371/journal.pone.0011495.t001
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two mutations were on the same allele. He presents high
functioning autism, without any remarkable medical history.
The MT1-A157V variant was identified in one individual from
the HGDP that originates from China (Miaozu). Two variants,
MT1-G166E and MT1-A266V, were frequent and no significant
difference was observed between patients and controls (p=0.12
and p=0.78)
Identification of MTNR1B non-synonymous variants
Ten non-synonymous mutations were identified for MTNR1B.
The MT2-R138C variant was identified in one proband and in
two controls (Table 1). The mother who transmitted the mutation
was born from consanguineous parents and was homozygous at
this locus (Table S1). She had no medical history except allergy.
The proband presents severe autism without language. Sleep was
not recorded as a major problem.
The MT2-V124I variant was detected in one patient, but not in
controls. Interestingly, the father of this proband, who also carried
the mutation, was treated with bright light therapy for seasonal
affective disorder as well as his brother from whom DNA was not
available. Seasonal mood change was not evaluated for the
proband because of mental retardation.
The MT2-R231H variant was identified in a proband with
Asperger syndrome without any comorbidity except strabism. DNA
of first degree relatives wasn’t available to test the segregation of the
variation.
The MT2-R330Q variant was identified in one of two affected
brothers and his father. The proband, who carried the mutation,
shows a more severe phenotype than his brother and exhibited
sleep disorder during early childhood whereas his brother did not.
The father has dyslexia.
The MT2-M120V variant was identified only in one control.
The MT2-A13V, MT2-A25T and MT2-A325V variants were
identified in three independent individuals from the HGDP that
originate from Asia (Pathan), Africa (San) and Asia (Cambodgian),
respectively.
One variant, MT2-G24E, was present in all populations with no
significant difference in allelic frequency between patients and
controls (p=0.13). The MT2-K243R was significantly more
frequent (19.3%) in individuals from African origin of the HDGP
sample than in patients and controls (2.7%61, p=7.3 E-19)
Identification of GPR50 non-synonymous variants
Three GPR50 non-synonymous polymorphisms (S493R, T532A
and I606V) and an in-frame 12 bp insertion/deletion polymorph-
ism (D502–505), which results in the loss of four amino acids
(Thr.Thr.Gly.His) were detected in ASD and controls (Table 2). A
GPR50 R126H variation was identified in one male control
(Table 2). In females, the frequency of each SNP was similar in
patients with ASD and in controls. In males, a significant
difference in allelic frequencies was observed for D502–505
(p=0.04) and T532A (P=0.02) between patients with ASD and
controls. When individuals from non European descent are
excluded, the association remained significant (P=0.04 and
P=0.03, respectively).
Functional analysis of non-synonymous variants within
the melatonin receptors
The functional properties of five MT1 and seven MT2 receptor
mutants and their respective wild type counterparts were
characterized in transiently and stably transfected HEK 293 and
COS cells. The electrophoretic mobility of mutant receptors in
SDS-PAGE experiments was indistinguishable from wild type
receptors with a predominant band at 60 and 50 kDa for MT1
and MT2, respectively (Figure 1). No significant differences in the
expression levels compared to wild type receptors were observed in
three independent experiments. Immunofluorescence microscopy
studies on intact cells revealed that MT1-I49N, MT1-G166E and
MT1-I212T mutants have severely reduced cell surface expression.
Table 2. Variants of the X-linked GPR50 identified in 295 patients with ASD and 362 controls.
Variation Allele Maj/Min Genomic position
a(pb) ASD Controls
(222 males and 73 females) (233 males and 129 females)
R126H G/A Chr X: 150348431
Male G/y 222 f(A)=0% G/y 232 A/y 1; f(A)=0.4%
Female G/G 73 f(A)=0% G/G 129 f(A)=0%
S493R G/A Chr X: 150349533
Male G/y 196 A/y 26; f(A)=12% G/y 201 A/y 32; f(A)=14%
Female G/G 137 A/G 9; f(A)=6% G/G 110 A/G 19; f(A)=7%
D502-505 Ins/del Chr X: 150349569
Male Ins/y 140 del/y 82; f(del)=37%* Ins/y 125 del/y 108; f(del)=46%
Female ins/ins 21 del/ins 35 del/del 17; f(del)=47% ins/ins 46 del/ins 60 del/del 23; f(del)=41%
T532A A/G Chr X: 150349649
Male A/y 142 G/y 80; f(G)=36%** A/y 123 G/y 110; f(G)=47%
Female A/A 21 A/G 35 G/G 17; f(G)=47% A/A 47 A/G 59 G/G 23; f(G)=41%
V606I G/A Chr X: 150349871
Male G/y 122 A/y 100; f(A)=45% G/y 119 A/y 114; f(A)=49%
Female G/G 22 A/G 33 A/A 18; f(A)=47% G/G 44 A/G 58 A/A 27; f(A)=43%
*p=0.04.
**p=0.02;
aHuman genome build NCBI36/hg18.
doi:10.1371/journal.pone.0011495.t002
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were mainly located in intracellular membrane compartments
(Figure 2A). All MT2 mutants were readily detectable at the cell
surface (Figure 2B). Cell surface expression of some intracellularly
retained GPCR mutants can be rescued in the presence of cell-
permeable antagonists as shown for vasopressin V2 receptor
mutants [21]. We therefore treated cells expressing MT1-I49N,
MT1-G166E or MT1-I212T for 16 h with the cell permeable
melatonin receptor antagonists 4-PPDOT or luzindole at 1 mM.
None of these treatments significantly modified the surface
expression of the mutant receptors (data not shown).
Ligand binding properties were assessed in 2(
125I)-iodomelato-
nin (
125I-MLT) saturation and competition binding experiments
(Table 3). All mutants did bind
125I-MLT and melatonin with high
affinity with the exception of the MT1-I49N mutant, which was
devoid of any binding activity. MT1-K334N, MT2-R138C, MT2-
R231H and MT2-K243R showed significantly increased Kd
values for
125I-MLT. However, this tendency was not confirmed
at the level of Ki values for melatonin in competition binding
experiments.
Coupling of mutant receptors to Gi proteins was assessed in
cAMP accumulation assays. Adenylyl cyclase was activated by
forskolin and the inhibitory effect of melatonin receptor activation
on this pathway monitored. Whereas wild type MT1 reduced
forskolin-stimulated cAMP levels by 30%, MT1-I49N and MT1-
I212T mutants were completely inactive and MT1-G166E and
Figure 1. Detection of MT1 and MT2 mutants by SDS-PAGE. Lysates from HEK 293 cells transiently expressing the indicated receptors were
separated by SDS-PAGE and analysis performed by Western blot using anti-Flag or anti-MT1 (MT1) (A) or anti-Myc or anti-MT2 antibodies (MT2) (B).
Similar results were obtained in three additional experiments.
doi:10.1371/journal.pone.0011495.g001
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receptors (Figure 3A, 3B). Most MT2 mutants were active in the
cAMP assay with the exception of MT2-R138C and to a lesser
extend the MT2-R231H and MT2-K243R mutants (Figure 4A).
Melatonin-promoted activation of the ERK1/2 pathway was used
as a second read-out to determine the signaling properties of
melatonin receptor mutants. Wild type and mutant receptors
showed the expected transient increase in ERK1/2 phosphoryla-
tion with a 3 and 2.5 fold maximal increase for MT1 and MT2,
respectively (Figure 3C, 4C). As in the cAMP assay, the MT1-I49N
mutant was completely inactive in the ERK1/2 assay (Figure 3C).
Interestingly, MT1-G166E and MT1-I212T mutants, which were
completely inactive in the cAMP assay, were clearly active,
although only partially, in the ERK1/2 assay. In addition, the
MT1-A266V mutant showed a partially impaired ability to
activate this pathway. ERK1/2 activation by MT2-G24E and
MT2-R330Q was similar to the MT2 wild type and in agreement
with the corresponding signaling properties for the cAMP pathway
(Figure 4C). All other mutants showed reduced activity towards
ERK1/2 activation. Whereas MT2-R138C was inactive in the
ERK1/2 assay and the cAMP assay, the MT2-V124I mutant was
inactive in the ERK1/2 assay but fully active in the cAMP assay
(Figure 4B) indicating that the latter mutant is biased towards the
cAMP pathway. Taken together, by analyzing a set of previously
unknown melatonin receptor mutants, several mutants with
modified functional properties were identified.
Discussion
We identified several mutants altering the functional properties
of the human melatonin receptors. The MT1-I49N mutant
showed the strongest phenotype as it was completely devoid of
any melatonin binding and signaling capacity and did not express
at the cell surface. The location of the mutation in the
transmembrane domain 1 (TM1) indicates a previously unknown
role of this domain in ligand binding of the MT1 receptor
(Figure 5A). Severely impaired cell surface expression was also
observed for MT1-G166E and MT1-I212T mutants. Treatment of
these receptor mutants with cell permeable antagonists did not
rescue cell surface expression indicating that conformational
stabilization of these mutants is unable to overcome the export
defect as has been shown previously for mutants of the vasopressin
V2 receptor [21].
The R138C mutation of MT2 is located in the NRY segment,
equivalent to the DRY motif that is conserved among all GPCRs
[22] (Figure 5B). This motif is believed to be important for the
activation mechanism of GPCRs and mutation of the central
arginine residue has been shown to result in constitutively active
receptors that are continually internalized and desensitized,
explaining their impaired signaling properties [22]. In the case
of the MT2-R138C mutant, no constitutive activity or internaliza-
tion was observed but rather an impaired capacity to regulate the
adenylyl cyclase pathway despite intact ligand binding properties.
Figure 2. A. Sub-cellular localization of MT1 mutants. COS cells transiently expressing the indicated receptors were permeabilized or not with
triton X-100 and total and surface exposed receptors detected by immunofluorescence microcopy with anti-Flag (MT1) antibodies. B. Sub-cellular
localization of MT2 mutants. COS cells transiently expression the indicated receptors were permeabilized or not with triton X-100 and total and
surface exposed receptors detected by immunofluorescence microcopy with anti-myc (MT2) antibodies. Similar results were obtained in three
additional experiments.
doi:10.1371/journal.pone.0011495.g002
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detected for GPR50 in the R126H mutant suggesting that this
orphan receptor might have some constitutive activity that is
modified in this mutant.
For MT1-G166E and MT1-I212T, the mutations are located in
the second extracellular loop (e2) and at the junction between
TM5 and the third intracellular loop (i3), respectively. Interest-
ingly, despite reduced cell surface expression and impaired
signaling through the cAMP pathway, these two mutants retained
some partial activity towards the ERK1/2 pathway. The
phenotype of these mutants is new and was completely
unpredictable. The e2 loop is increasingly recognized to play an
important role in ligand binding or gating of ligands to the ligand
binding pocket of GPCRs in the TM region [23,24]. The N-
terminal part of the i3 has been shown to be important for G
protein binding for several other receptors. Interestingly, whereas
the MT1-G166E and MT1-I212T mutants appear to be biased
towards the ERK1/2 pathway, the MT2-V124I mutant (mutation
located in TM3) appears to be biased towards the cAMP pathway,
as this mutant fully activates the cAMP pathway, but only partially
the ERK1/2 pathway. The spatial proximity of this mutant with
the conserved NRY motif at the end of TM3 might be important
for the phenotype of the MT2-V124I mutant. Taken together, we
describe here the first melatonin receptor mutants that show
various functional defects ranging from the absence of ligand
binding to impaired pathway-selective signaling properties.
Considering all populations, non-synonymous mutations were
less frequently observed in MTNR1A (4%61.9) compared to
MTNR1B (11.8%66). All MTNR1A variations were shown to affect
slightly or dramatically the function of the receptor whereas for
MTNR1B, 4 out of 7 variations were deleterious. When all
mutations were considered, only a significant increase of MTNR1B
non-synonymous mutations was observed in ASD compared to
controls (MTNR1A ASD: 3.6% vs controls: 4.4% Fisher exact test
P=0.48; MTNR1B ASD: 13.9% vs controls: 10.1%; P=0.038).
However, this association was no longer significant when only
MTNR1B mutations with deleterious effects were included in the
analysis (ASD: 4.7% vs controls 3%; P=0.11). Indeed, the relatively
frequent variation G24E and the rare variation M120V seem to
have no effect on the function of MT2. In contrast, MT2-K243R
significantly affects the Kd of the melatonin receptor and was
observedin19.3%ofindividuals from sub-SaharanAfrican descent.
This is contrasting with Europe and Asia, where the MT2-K243R
variation was observed with an allelic frequency of less than 4%.
Considering that MTNR1B is a susceptibility gene for diabetes, this
result suggests that this deleterious MT2 variation could represent a
risk factor for diabetes in sub Saharan African populations. Finally,
a significant association between ASD and two GPR50 variations
D502–505 and T532A was detected in affected males, but it did not
hold up after Bonferonni correction for multiple testing. Since
GPR50 influences neurite outgrowth [25] and the D502–505
variant was previously associated with bipolar disorder in females
[26], a possible association of this gene with ASD warrants further
genetic and functional studies.
Our results indicate that non-synonymous mutations within the
melatonin receptors do not represent a major risk factor for ASD.
These results therefore suggest that the melatonin signaling is
efficient in the majority of the patients with ASD, a feature
consistent with the great efficacy of melatonin treatment for sleep
disordersin patients suffering from thesedisorders[16,17,18,19,20].
Nevertheless, in a subgroup of patients, the presence of a deleterious
mutation may have phenotypic consequences. The proband
carrying the deleterious MT1-I49N mutation exhibited a delayed
sleep onset confirmed with actimetry. The father carrier of the
deleterious MT1-V124I mutation was treated for seasonal affective
disorder with bright light therapy. Interestingly, MT1-V124I was
recently identified in 1/109 patients with ASD and 0/188 controls
from Sweden [27]. In summary, human disorders caused or
influenced by abnormal clock setting remain to be characterized.
Given the importance of sleep for health, the exploration of the
causesofabnormalmelatoninsignalingiswarrantedforcliniciansto
provide adequate combination therapy.
Taken together, we present here the first comprehensive study
evaluating the genetic variability of the melatonin receptor
MTNR1A and MTNR1B genes in the general population and in
ADS patients. Although no clear association could be identified
between melatonin receptor variants and our ASD cohort, these
mutants will be very useful for future studies not only on ASD
patients but also on type 2 diabetes patients, for whom an
association of an intronic SNP in the MTNR1B gene has been
shown recently [4,5]. The functional characterization of the
mutants identified in the present study will provide new insights in
the structure-function relationship of MT1 and MT2 receptors and
can now be extended towards tissues expressing melatonin
receptor endogenously. The pathway-biased signaling of several
mutants in respect to the cAMP and MAPK pathway is of
particular interest demonstrating that melatonin receptors possess
the intrinsic property to reach pathway-selective conformational
states and opening the possibility that the phenotype of some
patients is associated with signaling pathway-specific effects.
Materials and Methods
Ethics Statement
This study was approved by the local Institutional Review
Board (IRB) and written inform consents were obtained for all
Table 3. Pharmacological characterization of MT1 and MT2
receptor mutants.
Receptor Kd (pM) Ki (pM)
MT1
Wt 154+/221 2800+/2690
I49R - -
G166E 220+/220 2300+/2870
I212T 101+/252 9 0 0 +/2900
A266V 224+/243 1350+/2430
K334N 395+/268** 3270+/21700
MT2
Wt 125+/220 3230+/2627
G24E 191+/231 4090+/21400
M120V 194+/256 4530+/2660
V124I 165+/217 6050+/2550
R138C 234+/225 * 4700+/2245
R231H 417+/259 *** 1850+/2820
K243R 659+/229 *** 1780+/2850
R330Q 90+/220 4300+/2520
Kd values for
125I-MLT were determined in radioligand saturation experiments
with increasing concentration of
125I-MLT. IC50 values for melatonin were
determine in competition bindings experiments with 200 pM of
125I-MLT. Ki
values were calculated from IC50 values using the Cheng-Prussof formula
Ki=IC50/(1+[L]/Kd. Experiments were repeated 3–7 times (*, P,0.05; **,
P,0.01; ***, P,0.001 vs wt).
doi:10.1371/journal.pone.0011495.t003
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PLoS ONE | www.plosone.org 6 July 2010 | Volume 5 | Issue 7 | e11495participants of the study. The local IRB are Comite ´s de Protection
des Personnes I ˆle-de-France VI Sis Ho ˆpital Pitie ´-Salpe ˆtrie `re 75013
PARIS for France and the Sahlgrenska Academy Ethics
committee, University of Gothenburg for Sweden. For all
probands (245 children and 50 adults), written inform consent
was signed by the patients or parents or the legal representative.
Subjects
Families with ASD were recruited by the Paris Autism Research
International Sibpair study at specialized clinical centers in seven
countries (France, Sweden, Norway, Italy, Belgium, Austria and
the United States). Diagnosis was based on clinical evaluation by
experienced clinicians, DSM-IV criteria, and the Autism Diag-
nostic Interview-Revised (ADI-R) [28]. In Sweden, the Diagnostic
Interview for Social and Communication Disorders (DISCO-10)
[29] was used instead of the ADI-R in some cases. Patients with
Asperger syndrome were evaluated with the Asperger Syndrome
Diagnostic Interview [30]. The study sample (n=295, 222 males
and 73 females) included 222 patients with autistic disorder and 61
with Asperger syndrome; 12 individuals narrowly missed the
criteria for autistic disorder and were considered to have pervasive
developmental disorder not otherwise specified (PDD-NOS). They
were unrelated patients. When a rare variation was identified, the
segregation was studied in first degree relatives. There were 274
Caucasians, 5 sub-Saharian Africans, 3 Asians, and 13 families of
mixed ethnicity. The control sample (n=362) comprised 100
French (60 males, 40 females) and 262 Swedish individuals (173
males, 89 females) all of European descent. In addition, a sample
of 284 individuals from the human genome diversity panel
(HGDP) [31] was screened for rare variants of MTNR1A and
Figure 3. Signaling of MT1 mutants through the cAMP and ERK pathways. HEK 293 cells were transiently (A, B) or stably (C–F) transfected
with the indicated receptors. Inhibition of the cAMP pathway was measured by stimulating cells with forskolin alone (10 mM) or with forskolin and (A)
10 nM or (C) increasing concentration of melatonin for 60 min. Cyclic AMP levels were determined as described in Materials and Methods. ERK
activation was measured by incubating cells with 100 nM melatonin for the indicated times (C–F). Phospho-ERK and ERK levels were determined as
described in Materials and Methods. Data are means 6 S.E.M. of three independent experiments each performed in duplicate (*, P,0.05; **, P,0.01;
***, P,0.001 vs wt).
doi:10.1371/journal.pone.0011495.g003
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from sub-Saharian Africa and 89 from Europe (Table S2).
Genetic screening of the melatonin receptors
Blood samples were collected and DNA was extracted by the
phenol/chloroform method. Mutation screening was performed
by direct sequencing of the PCR products. All PCRs were
performed with Qiagen HotStar Taq kit. Two PCR protocols
were used: (i) Standard protocol: 95uC for 15 min, followed by 35
cycles at 99uC for 30 s, 55 to 65uC for 20 s, 72uC for 60 to 90 s,
with a final cycle at 72uC for 10 min; and (ii) Touchdown
protocol: 95uC for 15 min followed by 20 cycles at 99uC for 30 s,
60–50uC for 30 s, and 72uC for 1 min, followed by 20 cycles at
99uC for 30 s, 50u for 10 s, and 72uC for 1 minute, with a final
Figure 4. Signaling of MT2 mutants through the cAMP and ERK pathways. HEK 293 cells were transiently (A, B) or stably (C–E) transfected
with the indicated receptors. Inhibition of the cAMP pathway was measured by stimulating cells with forskolin alone (10 mM) or with forskolin and (A)
10 nM or (C) increasing concentration of melatonin for 60 min. Cyclic AMP levels were determined as described in Materials and Methods. ERK
activation was measured by incubating cells with 100 nM melatonin for the indicated times (C–E). Phospho-ERK and ERK levels were determined as
described in Materials and Methods. Data are means 6 S.E.M. of three independent experiments each performed in duplicate (*, P,0.05; **, P,0.01;
***, P,0.001 vs wt).
doi:10.1371/journal.pone.0011495.g004
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table S3). PCR products were sequenced with the BigDye
Terminator Cycle Sequencing Kit (V3.1, Applied Biosystems).
Samples were then subjected to electrophoresis, using an ABI
PRISM genetic analyzer (Applied Biosystems). Each PCR product
was sequenced using both forward and reverse primers. When a
non-synonymous mutation was identified, PCR and sequenced
were performed again from a new batch of DNA.
Functional screening of the melatonin receptors
The immunofluorescence experiments and immunoblots of the
MTNR1A (MT1) and MTNR1B (MT2) variants were performed
using COSM1 cells transfected with each plasmid and seeded the
day after onto sterile 25 mm polyL-lysine-coated coverslips. After
24 h, cells were fixed with PBS-PFA 4% for 15 min. After a
10 min permeabilization step in PBS-Triton X-100 0.1%, cells
were blocked for 1 h with 3% BSA in PBS. Cells were
Figure 5. Topology of MT1 and MT2 receptors. The amino acid sequence of MT1 (A) and MT2 (B) receptors are shown and amino acids identified in
receptor variants are highlighted in black (,). Amino acids known to be involved in
125I-MLT binding are circled in black. The NRY motif is highlighted in
grey (C-ter, carboxyl terminal domain; e1, e2, e3, extracellular loops 1–3; i1, i2, i3, intracellular loops 1–3; N-ter, amino terminal domain).
doi:10.1371/journal.pone.0011495.g005
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monoclonal anti-Flag at 2 mg/ml (Sigma, MO) or monoclonal
anti-myc 0.2 mg/ml (Santa Cruz, CA), followed by 20 min with
the secondary antibody FITC anti-mouse. For immunoblots,
crude membrane preparations were performed as described
previously [32]. Proteins were loaded on 10% SDS-PAGE and
transferred to nitrocellulose membranes (Whatman). After block-
ing with 5% non fat dried milk, membranes were incubated with
primary antibodies: rabbit anti-MT1, rabbit anti-MT2, mouse
anti-p-ERK1/2 (Santa Cruz). Immunoreactivity was revealed
using IRDye infrared secondary antibodies using the LI-COR
Odyssey infrared imaging system (Courtaboeuf, France).
The cellular localization of melatonin receptors was assessed on
COS cells transfected with the different Flag-tagged MT1 mutants
or Myc-tagged MT2 mutants fixed with 4% paraformaldehyde in
PBS on ice for 20 min, in the presence or not of 0.1% Triton X-
100. After several PBS washes, cells were incubated in PBS
containing 2% BSA for 1 h then in the same buffer containing
anti-Flag M2 or anti-Myc 9E10 antibodies (1 h on ice). Cells were
then incubated with Cyanin3-coupled secondary antibody. The
fluorescence was measured by FACS.
Binding experiments were performed on crude membrane
preparation and 2(
125I)-iodomelatonin (
125I-MLT) (PerkinElmer)
radioligand as described previously [32]. Competition binding
assays were carried out on crude membranes at 200 pM
125I-MLT
and increasing concentrations of melatonin. (Sigma, St Louis,
MO) as described previously [33].
The cAMP-Gi activation was determined by measuring cyclic
AMP levels by HTRF using the ‘‘cAMP femto2’’ kit (Cisbio,
Bagnols-sur-Ce `ze, France). Cells in suspension were stimulated by
10 mM forskolin, alone or in the presence of 10 nM melatonin for
30 min. Samples were analyzed with a Pherastar apparatus (BMG
Labtech, Offenburg, Germany). For the MAP-kinase activation,
cells were stimulated with 10 nM melatonin and the kinetics of
ERK1/2 phosphorylation was determined by immunoblotting.
Phosphorylated ERK1/2 were detected by anti-phospho-ERK
antibody (sc-7383, Santa-Cruz). Levels of loaded proteins were
compared by detection of ERK2 (sc-154, Santa-Cruz).
Actimetry
Actimetry was measured for the proband with the MT1-I49N
mutation with an Actiwatch bracelet. Results were analyzed with
Actiwatch Activity and Sleep Analysis (5.24 version).
Supporting Information
Table S1 Clinical observations of the families carrying rare
MTNR1A and MTTNR1B mutations.
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